CTSS and aortic aneurysm: Eli Lilly’s non-covalent inhibitor LY3000328 reduced plasma CTSS activity in phase I and advanced to phase II for aortic aneurysm; its derivatives also demonstrate immunomodulatory effects in bladder cancer by regulating T-cell activity (91).